ATE531725T1 - Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen - Google Patents
Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechenInfo
- Publication number
- ATE531725T1 ATE531725T1 AT08726179T AT08726179T ATE531725T1 AT E531725 T1 ATE531725 T1 AT E531725T1 AT 08726179 T AT08726179 T AT 08726179T AT 08726179 T AT08726179 T AT 08726179T AT E531725 T1 ATE531725 T1 AT E531725T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- egfr
- inhibitor
- gene
- respond
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 230000014509 gene expression Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90369407P | 2007-02-27 | 2007-02-27 | |
| PCT/US2008/002602 WO2008106175A2 (en) | 2007-02-27 | 2008-02-27 | Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531725T1 true ATE531725T1 (de) | 2011-11-15 |
Family
ID=39716322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08726179T ATE531725T1 (de) | 2007-02-27 | 2008-02-27 | Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20080206777A1 (de) |
| EP (2) | EP2413142B1 (de) |
| AT (1) | ATE531725T1 (de) |
| DK (2) | DK2114990T5 (de) |
| ES (2) | ES2376978T3 (de) |
| WO (1) | WO2008106175A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9814271A (pt) * | 1997-12-12 | 2001-03-20 | Digene Corp | Determinação de doenças relacionadas com o vìrus do papiloma humano |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7906342B2 (en) * | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
| CA2726396C (en) * | 2008-04-17 | 2019-03-19 | Qiagen Gaithersburg, Inc. | Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid |
| WO2010062546A1 (en) | 2008-10-27 | 2010-06-03 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay on an automated platform |
| EP2419522A4 (de) * | 2009-04-17 | 2012-10-31 | Glen Weiss | Verfahren und kits zur prognose des therapieergebnisses von tyrosinkinasehemmern |
| JP5738278B2 (ja) | 2009-05-01 | 2015-06-24 | キアジェン ゲイサーズバーグ インコーポレイテッド | 試料中のｒｎａスプライシング形態を検出するための非標的増幅法 |
| CA2773320C (en) | 2009-09-14 | 2018-02-20 | Qiagen Gaithersburg, Inc. | Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media |
| WO2011094528A2 (en) | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Method of determining and confirming the presence of an hpv in a sample |
| AU2011210734B2 (en) * | 2010-01-29 | 2017-02-09 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| JP2013520681A (ja) * | 2010-02-24 | 2013-06-06 | バイオデシックス・インコーポレイテッド | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
| AU2011255638B2 (en) | 2010-05-19 | 2016-08-25 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| WO2012094059A2 (en) * | 2010-11-10 | 2012-07-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of diagnosing early stage non-small cell lung cancer |
| CA2828224A1 (en) | 2011-02-24 | 2012-08-30 | Qiagen Gaithersburg, Inc. | Materials and methods for detection of hpv nucleic acids |
| CN103926408A (zh) * | 2014-04-30 | 2014-07-16 | 天津医科大学肿瘤医院 | 一种用于预测nsclc病人预后的试剂盒及骨桥蛋白作为特异标记物的应用 |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN116098856B (zh) * | 2023-01-16 | 2024-06-21 | 四川大学华西医院 | 光固化水凝胶复合核酸传递系统及治疗脊髓损伤的药物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5288477A (en) * | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
| FI941572A7 (fi) * | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| US6482795B1 (en) * | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
| ATE395419T1 (de) * | 1997-07-03 | 2008-05-15 | Asahi Kasei Pharma Corp | Neue mapk kinase |
| ATE347102T1 (de) | 1998-02-25 | 2006-12-15 | Us Health | Zellulare anordnungen für schnelle molekulare profilidentifizierung |
| US6218114B1 (en) | 1998-03-27 | 2001-04-17 | Academia Sinica | Methods for detecting differentially expressed genes |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
| US6582946B1 (en) * | 2001-03-12 | 2003-06-24 | Applera Corporation | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| US6727072B2 (en) * | 2001-05-01 | 2004-04-27 | Dako Corporation | EGF-r detection kit |
| US20030194734A1 (en) | 2002-03-29 | 2003-10-16 | Tim Jatkoe | Selection of markers |
| EP1509230B1 (de) * | 2002-06-05 | 2007-01-03 | Cedars-Sinai Medical Center | Gefitinib (iressa) zur behandlung von krebs |
| US8067152B2 (en) * | 2006-02-27 | 2011-11-29 | The Fred Hutchinson Cancer Research Center | Liver cancer biomarkers |
-
2008
- 2008-02-27 ES ES08726179T patent/ES2376978T3/es active Active
- 2008-02-27 ES ES11008690T patent/ES2412432T3/es active Active
- 2008-02-27 DK DK08726179.8T patent/DK2114990T5/da active
- 2008-02-27 AT AT08726179T patent/ATE531725T1/de active
- 2008-02-27 EP EP11008690.7A patent/EP2413142B1/de not_active Not-in-force
- 2008-02-27 EP EP08726179A patent/EP2114990B9/de not_active Not-in-force
- 2008-02-27 US US12/072,651 patent/US20080206777A1/en not_active Abandoned
- 2008-02-27 WO PCT/US2008/002602 patent/WO2008106175A2/en not_active Ceased
- 2008-02-27 DK DK11008690.7T patent/DK2413142T3/da active
- 2008-09-22 US US12/284,397 patent/US8129125B2/en not_active Expired - Fee Related
-
2009
- 2009-06-08 US US12/480,076 patent/US8088589B2/en not_active Expired - Fee Related
-
2011
- 2011-12-22 US US13/334,881 patent/US8900820B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080206777A1 (en) | 2008-08-28 |
| US20110189691A1 (en) | 2011-08-04 |
| EP2413142B1 (de) | 2013-06-05 |
| WO2008106175A3 (en) | 2008-11-20 |
| DK2114990T5 (da) | 2012-05-07 |
| US8900820B2 (en) | 2014-12-02 |
| US8129125B2 (en) | 2012-03-06 |
| EP2413142A1 (de) | 2012-02-01 |
| EP2114990A4 (de) | 2010-04-07 |
| EP2114990B9 (de) | 2012-03-28 |
| US8088589B2 (en) | 2012-01-03 |
| WO2008106175A2 (en) | 2008-09-04 |
| EP2114990A2 (de) | 2009-11-11 |
| ES2376978T3 (es) | 2012-03-21 |
| DK2413142T3 (da) | 2013-07-22 |
| DK2114990T3 (da) | 2012-01-16 |
| ES2412432T3 (es) | 2013-07-11 |
| EP2114990B1 (de) | 2011-11-02 |
| US20120094311A1 (en) | 2012-04-19 |
| US20090263819A1 (en) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE531725T1 (de) | Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen | |
| WO2008073177A3 (en) | Expression profiles associated with irinotecan treatment | |
| CY1125190T1 (el) | Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα | |
| Gu et al. | Correlation between reversal of DNA methylation and clinical symptoms in psoriatic epidermis following narrow-band UVB phototherapy | |
| ATE406463T1 (de) | Methode zur krebsdiagnose mittels nachweis von dna und rna im kreislauf | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| WO2008088854A3 (en) | Genetic markers for predicting responsiveness to combination therapy | |
| BRPI0518086A (pt) | métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação | |
| BR112015023783A2 (pt) | método para diagnóstico e tratamento de metastase no câncer | |
| WO2006091776A3 (en) | Biomarkers for predicting prostate cancer progression | |
| WO2009015233A3 (en) | Gefitinib sensitivity-related gene expression and products and methods related thereto | |
| Marino et al. | Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression | |
| ATE541946T1 (de) | Verfahren und system zur bestimmung von genkopiezahlvarianten | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| HK1213946A1 (zh) | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 | |
| WO2012119113A3 (en) | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures | |
| BRPI0907637A8 (pt) | biomarcadores p53 | |
| WO2008148115A8 (en) | Methods, systems, and kits for evaluating multiple sclerosis | |
| PH12014502410A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression | |
| EA201992026A1 (ru) | Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5 | |
| SI2838998T1 (en) | EGFR AND ROS1 PRI CRAK | |
| WO2009003706A3 (en) | Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones | |
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| BRPI0412110A (pt) | genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie |